Curaleaf and MCCS partner for medical cannabis training in the UK

The UK and Germany are leading Europe’s medical cannabis boom, but their paths are very different. Releaf’s CEO Tim Kirby says: “A lot of operators in Germany are drinking their own champagne. It’s very easy to feel successful when there’s huge demand, but that doesn’t mean you’re good at it.” Since launching in February 2024, Releaf has grown into one of the UK’s largest clinics, serving 300 patients a day and attracting 300,000 monthly visitors to its site. Now, the clinic is bringing its tech-focused, patient-first digital ecosystem to Germany, aiming to be a top-three clinic within six months. 🔗 https://lnkd.in/entjV9b7 Could this approach redefine the German medical cannabis market?

With 10+ years counseling patients on the use of medical cannabis, here are 5 tips I wish I had known earlier in my career. For medical students entering this rapidly evolving field, gaining a nuanced understanding of medical cannabis is essential. This knowledge can empower future healthcare providers to make informed decisions, bridging the gap between conventional medical practices and innovative therapies. After more than 10 years of treating patients with cannabis, here are five critical insights I wish I knew when first recommending medical cannabis to my patients. #ACS #Cannaspecialists #Cannabis #Medicalcannabis #Medicalstudents #Residents

In this observational study of patients with chronic pain using opioids, medical cannabis authorization was not associated with a statistically significant decrease in opioid milligram equivalents (OME) over time. https://ow.ly/OtL650X0CoX

Could medical cannabis unlock a £13.3 billion boost for the UK economy? That’s the question at the heart of our latest campaign with Curaleaf Clinic. The research, developed with Cebr, reveals how medical cannabis could help thousands of people with long-term health conditions get back to work, restoring independence for individuals and injecting billions into the economy The challenge is huge: - 2.8 million people in the UK are currently locked out of employment by long-term illness - 62% say they’ve run out of traditional treatment options. The report calls for clearer NHS pathways, wider access, and government-funded research to give patients real choice and the chance to rebuild their lives At the centre of the campaign are powerful patient voices - like Fatma, who told us: “Not being able to get out of bed and go to work made me feel as if my identity was being stripped away. I now have the ability to work, lead a team, and regain my independence.” The story has already made headlines across the Mirror, Express, Daily Star and Metro. Read the full report linked in the comments A huge thank you to Curaleaf Clinic, Cebr and the patients who openly shared their experiences

The team at Ethos Cannabis believes medical cannabis care should be rooted in science, not guesswork. In her latest op-ed, Brooke Worster, MD, FACP, Chief Medical Consultant at Ethos Cannabis & Enterprise Director of Supportive Oncology at Jefferson Health, shares how Ethos’ partnership with Thomas Jefferson University is generating real-world data to better understand how patients use cannabis—and translating those insights into education, product development, and improved patient care. By aligning healthcare providers, dispensary staff, and researchers, we’re working to bridge the gap between research and real-world use, ensuring patients receive informed, compassionate guidance. 📖 Read Dr. Worster’s full piece to see how Pennsylvania’s program can set a national example for cannabis research and care: https://lnkd.in/gvwcSnqU

Decontamination is one of the most pressing topics in medical cannabis — and Cryopasteurization is setting the benchmark for innovation and safety. This state-of-the-art technology ensures microbial control without compromising product integrity, paving the way for safer and more consistent cannabis-based therapeutics. #MedicalCannabis #Cryopasteurization #Decontamination

This is the BS we're up against: "Medical cannabis companies regularly use associations with academia and academic research to imply that their products are safe and effective before these claims are causally confirmed. This practice may mislead patients, policymakers, and the public into believing unconfirmed claims about the safety and efficacy of cannabis and cannabis-derived products." The Use of Academic Research in Medical Cannabis Marketing: A Qualitative and Quantitative Review of Company Websites https://lnkd.in/ex6rfkGT #cannabis #medicine #patients #doctors @nejm @JAMA_current @CannabisJrnl

In the United Kingdom 🇬🇧, we’re proud to announce that Loomis Pharma is now an official member of the UK Cannabis Trades Association (CTA). Our work focuses exclusively on the secure transport of prescribed medical cannabis— supporting patients, healthcare providers, and the wider healthcare system. By joining the CTA, we are strengthening our commitment to: ✅ Promoting high standards and ethical practices ✅ Staying informed with the latest regulatory and industry developments ✅ Collaborating with peers to help shape a safe, responsible and compliant UK sector This membership is another important step in our mission to build trust and support high standards across the prescribed medical cannabis supply chain in the UK. #LoomisPharma #UK #UnitedKingdom #CannabisTradesAssociation #CTA #PharmaLogistics #MedicalCannabis

Today, the Spanish Council of Ministers has approved a Royal Decree regulating the medical use of cannabis through standardized preparations. The regulation aims to provide a therapeutic alternative for patients who do not respond to conventional treatments, particularly those suffering from chronic refractory pain, severe epilepsy, or spasticity associated with multiple sclerosis. “The approval of Spain’s medical cannabis Royal Decree is a long-awaited and important milestone,” said Michael Sassano, Founder and Interim CEO of SOMAÍ. “While it marks the beginning of patient access in Spain, it sets the foundation for a structured, evidence-based framework that can evolve with science and experience. As one of Europe’s leading EU-GMP extract manufacturers, SOMAÍ is ready to support this new chapter by sharing expertise, ensuring pharmaceutical consistency, and helping healthcare professionals gain confidence in cannabinoid-based therapies.” Read the full text: https://lnkd.in/dMZuVQmr

We’re proud to announce a new partnership between Curaleaf Laboratories and The Medical Cannabis Clinicians Society - a collaboration designed to close the education gap that continues to hold back patient access in the UK. While the UK is now the second largest medical cannabis market in Europe, fewer than 10% of the patients who could benefit are currently receiving treatment. One of the biggest barriers? A lack of education for clinicians. Education has always been central to Curaleaf’s strategy, and this partnership builds on that foundation, creating a stronger platform to empower prescribers and ultimately improve patient care. As Professor Michael Barnes Chair of MCCS, said: “The Society is very grateful to have the support of Curaleaf Laboratories… with the ultimate goal of enabling more patients to benefit from these therapies.” We’re excited to be taking this step forward — because with the right knowledge and support, we believe the UK medical cannabis journey is only just beginning. Read more about our partnership via Business of Cannabis here: https://brnw.ch/21wVVbm